

The Editors have received information that three articles [1–3] on the subject of HER2 amplified breast cancer, previously published by this Journal, contained errors in the citation of methods and interpretation of primary data cited by the authors. Although the general conclusion of the papers remains unchanged, the Editors of *The Oncologist* bring these inaccuracies to the attention of readers and suggest that this information should be taken into account in making reference to these three articles [1–3] and in judging their content. This statement has been reviewed by the senior authors, who endorse this Expression of Concern.

#### REFERENCES

1. Ross JS, Fletcher JA. The HER-2/*neu* oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. *The Oncologist* 1998; 3:237–252.
2. Ross JS, Fletcher JA, Linette GP et al. The Her-2/*neu* gene and protein in breast cancer 2003: Biomarker and target of therapy. *The Oncologist* 2003; 8:307–325.
3. Ross JS, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. *The Oncologist* 2009;14:320–368.